Filing of the 2025 Universal Registration Document




Filing of the 2025 Universal Registration Document

Paris, 2 March 2026 – Clariane (CLARI – ISIN: FR0010386334) announces the release of its 2025 Universal Registration Document.

The 2025 Universal Registration Document was filed with the French Financial Markets
Authority on 27 February 2026 in ESEF format, under number D.26-0054.

This 2025 Universal Registration Document, established for the financial year ended on
31 December 2025, includes in particular:

• the annual financial report and the integrated report,
• the report of the Board of Directors on corporate governance,
• the sustainability information and the certification report of these information,
• the reports of the Statutory Auditors on annual and consolidated accounts and
  information concerning their fees,
• the description of the share buyback program.

The 2025 Universal Registration Document is available on the Company’s website (www.clariane.com – Investor section), as well as on the French Financial Markets
Authority’s website (www.amf-france.org).

The Universal Registration Document is also available, free of charge, at the Company’s registered office, located in Paris (8^th), 21-25, rue Balzac.

Next events:

23 April 2026 – First quarter 2026 revenue

12 May 2026 – Annual General Meeting

Attachments

• Filling of the Universal Registration Document 2025 (VDEF)
• Filling of the Universal Registration Document 2025 (VDEF)

Evaxion to announce business update and full year 2025 financial results on March 5, 2026




Evaxion to announce business update and full year 2025 financial results on March 5, 2026

COPENHAGEN, Denmark, March 2, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM.

Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer




Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

• Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancer
• Study provides additional proof of concept that combining alnodesertib with DNA-damaging agents in high replication stress cancers delays tumor progression
• Phase 2 studies with higher dose alnodesertib plus irinotecan are ongoing in ATM-negative colorectal and pancreatic cancers

CAMBRIDGE, United Kingdom and NEW YORK, March 2, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today reported data from a randomized Phase 2a clinical study (NCT04657068). The trial evaluated Artios’ lead candidate, alnodesertib, in combination with gemcitabine versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The results were presented by Principal Investigator Antonio Gonzalez-Martin, MD, PhD, Director of the Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra, in a poster session at the 27^th European Society of Gynaecological Oncology (ESGO) Annual Meeting held in Copenhagen, Denmark, from February 26-28, 2026.

Alnodesertib is a highly potent, oral, selective inhibitor of the protein kinase ataxia telangiectasia and Rad3-related (ATR). ATR is a key regulator of the cellular response to replication stress, which can occur endogenously or exogenously, for example, via chemotherapy. Multiple cancer types, including HGSOC, are characterized by high endogenous replication stress and rely on ATR to repair damaged DNA before cancer cells progress through the cell cycle. Combining the ATR inhibitor alnodesertib with the DNA-damaging agent gemcitabine amplifies replication stress and has demonstrated additional and more durable clinical benefit.

“This randomized Phase 2a study evaluating a low dose of alnodesertib and the labelled dose of gemcitabine in platinum-resistant ovarian cancer achieved the primary endpoint of progression-free survival, further establishing proof-of-concept in our differentiated approach of inhibiting ATR in tumors with high replication stress,” said Ian Smith, Chief Medical Officer of Artios. “These data support further investigation of alnodesertib plus DNA-damaging agents, which we are currently evaluating at higher doses of alnodesertib plus low dose irinotecan in patients with colorectal and pancreatic cancer.”

Highlights of clinical data presented at ESGO 2026:

In the Phase 2a study, 64 patients with platinum-resistant HGSOC were randomized 1:1 to receive a low dose of alnodesertib plus standard-of-care gemcitabine or the same dose of gemcitabine alone, stratified by platinum-free interval. The gemcitabine treatment with or without alnodesertib was administered during a 21-day cycle at the recommended phase 2 dose, which included alnodesertib (50mg) on days 2 – 4 and 9 – 11, and gemcitabine (800mg/m²) on days 1 and 8.

• Combining a low dose of alnodesertib with gemcitabine was statistically significant (p<0.1, one-sided test) and improved progression-free survival (PFS) with a 29% reduction in the risk of progression or death compared with gemcitabine alone
  • • 6-month PFS rate was 34% with low dose alnodesertib plus gemcitabine compared to 23% with gemcitabine alone
    • 13 patients (41%) initially randomized to gemcitabine alone were crossed over to the combination with low dose alnodesertib, following disease progression; several patients experienced longer and clinically relevant disease control when low dose alnodesertib was added to the treatment regimen
    • Key secondary endpoints of overall response rate and overall survival were comparable in both treatment arms, with overall survival analysis confounded by a 41% cross-over rate
• The most frequent adverse events were asthenia, pyrexia, and hematologic and gastrointestinal toxicities
  • • Overall rates of grade ≥3 adverse events were similar in both arms (66% with low dose alnodesertib plus gemcitabine vs 63% with gemcitabine alone), although grade ≥3 anemia and thrombocytopenia were more common with the combination
    • No treatment‑related deaths or cases of febrile neutropenia were reported in either arm of the study

“The encouraging clinical signals we observed in patients when low dose alnodesertib was added to gemcitabine suggest that this approach warrants further evaluation,” said Principal Investigator, Antonio Gonzalez-Martin, MD, PhD, Director of the Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra. “With approximately 70% of patients with ovarian cancer eventually relapsing following platinum-based chemotherapy, there is a high unmet need for promising new therapies like alnodesertib to improve clinical outcomes in platinum-resistant HGSOC and other tumors with high replication stress.”

About alnodesertib
Alnodesertib, formerly known as ART0380, is a potential first-in-class, orally administered, selective small molecule inhibitor of ataxia-telangiectasia and Rad3-related protein (ATR). It is designed to be used in combination with DNA‑damaging agents and is being evaluated across multiple tumor types characterized by high endogenous replication stress. Artios’ differentiated approach combines alnodesertib with low‑dose irinotecan to exploit replication stress in cancers such as ATM protein–deficient metastatic colorectal and pancreatic cancer, and other chemotherapies, like gemcitabine, to address platinum-resistant high-grade serous ovarian cancer (HGSOC).

About Artios Pharma Ltd.
Artios’ mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. Its three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib, the DNA polymerase theta (Polθ) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads. Together, these programs are designed to eliminate cancer cells’ survival mechanisms, driving cancer cell death and improving clinical outcomes.

Visit our website at www.artios.com to learn more about Artios.

For more information, please contact:
Trophic Communications
Jacob Verghese or Verena Schossmann
Tel: +49 151 7441 6179
Email: artios@trophic.eu

Ardena Appoints Paul Edwards as Chief People Officer




Ardena Appoints Paul Edwards as Chief People Officer

Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical contract development and manufacturing organizatin (CDMO) and bioanalytical contract research organization (CRO) advancing precision medicines, today announces the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, strengthening organizational capability and supporting the company’s continued international growth. 

Paul brings over 30 years of Human Resources leadership experience in complex, science-driven organizations. He joins Ardena after 16 years at Catalent Pharma Solutions, where he most recently served as Vice President, Human Resources. In that role, he led international HR teams across multiple business units and geographies, shaping people strategies aligned with operational expansion, organizational design and leadership development. 

At Ardena, Paul will focus on strengthening leadership capability, building a high-performance culture and ensuring the organization is structured to support productivity, speed and scalability. His mandate includes simplifying structures, clarifying accountability and developing the talent and engagement frameworks required to enable efficient execution across the business. 

Jeremie Trochu, Chief Executive Officer of Ardena, commented: “I’m delighted to welcome Paul onto our team. His track record in leading global HR organizations within the biopharma services sector makes him a very strong addition to our executive team. As Ardena continues to expand its capabilities and footprint internationally, investing in our people, leadership and culture is essential to delivering for our customers. Paul will play a key role in ensuring our organization evolves in line with our strategic ambitions.” 

Paul Edwards added: “Ardena has a clear strategy and very strong scientific and technical foundations. I look forward to working with my new colleagues across the organization to further develop our leadership capability, support talent development and foster a high-performance culture that enables sustainable growth.” 

Paul holds a joint honours degree in Law and Politics from Durham University in the United Kingdom and is based in New Jersey, USA. 

About Ardena 

Ardena is a specialist pharmaceutical CDMO and bioanalytical CRO dedicated to advancing precision medicines. Through integrated services spanning drug substance, drug product, nanomedicines, bioanalytical services and CMC regulatory support, Ardena supports innovative and complex molecules from development to commercialization. 

Attachment

• Paul Edwards, Chief People Officer, Ardena

Evaxion to announce business update and full year 2025 financial results on March 5, 2026




Evaxion to announce business update and full year 2025 financial results on March 5, 2026

COPENHAGEN, Denmark, March 2, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM.

Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer




Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

• Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancer
• Study provides additional proof of concept that combining alnodesertib with DNA-damaging agents in high replication stress cancers delays tumor progression
• Phase 2 studies with higher dose alnodesertib plus irinotecan are ongoing in ATM-negative colorectal and pancreatic cancers

CAMBRIDGE, United Kingdom and NEW YORK, March 2, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits for patients with cancer, today reported data from a randomized Phase 2a clinical study (NCT04657068). The trial evaluated Artios’ lead candidate, alnodesertib, in combination with gemcitabine versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The results were presented by Principal Investigator Antonio Gonzalez-Martin, MD, PhD, Director of the Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra, in a poster session at the 27^th European Society of Gynaecological Oncology (ESGO) Annual Meeting held in Copenhagen, Denmark, from February 26-28, 2026.

Alnodesertib is a highly potent, oral, selective inhibitor of the protein kinase ataxia telangiectasia and Rad3-related (ATR). ATR is a key regulator of the cellular response to replication stress, which can occur endogenously or exogenously, for example, via chemotherapy. Multiple cancer types, including HGSOC, are characterized by high endogenous replication stress and rely on ATR to repair damaged DNA before cancer cells progress through the cell cycle. Combining the ATR inhibitor alnodesertib with the DNA-damaging agent gemcitabine amplifies replication stress and has demonstrated additional and more durable clinical benefit.

“This randomized Phase 2a study evaluating a low dose of alnodesertib and the labelled dose of gemcitabine in platinum-resistant ovarian cancer achieved the primary endpoint of progression-free survival, further establishing proof-of-concept in our differentiated approach of inhibiting ATR in tumors with high replication stress,” said Ian Smith, Chief Medical Officer of Artios. “These data support further investigation of alnodesertib plus DNA-damaging agents, which we are currently evaluating at higher doses of alnodesertib plus low dose irinotecan in patients with colorectal and pancreatic cancer.”

Highlights of clinical data presented at ESGO 2026:

In the Phase 2a study, 64 patients with platinum-resistant HGSOC were randomized 1:1 to receive a low dose of alnodesertib plus standard-of-care gemcitabine or the same dose of gemcitabine alone, stratified by platinum-free interval. The gemcitabine treatment with or without alnodesertib was administered during a 21-day cycle at the recommended phase 2 dose, which included alnodesertib (50mg) on days 2 – 4 and 9 – 11, and gemcitabine (800mg/m²) on days 1 and 8.

• Combining a low dose of alnodesertib with gemcitabine was statistically significant (p<0.1, one-sided test) and improved progression-free survival (PFS) with a 29% reduction in the risk of progression or death compared with gemcitabine alone
  • • 6-month PFS rate was 34% with low dose alnodesertib plus gemcitabine compared to 23% with gemcitabine alone
    • 13 patients (41%) initially randomized to gemcitabine alone were crossed over to the combination with low dose alnodesertib, following disease progression; several patients experienced longer and clinically relevant disease control when low dose alnodesertib was added to the treatment regimen
    • Key secondary endpoints of overall response rate and overall survival were comparable in both treatment arms, with overall survival analysis confounded by a 41% cross-over rate
• The most frequent adverse events were asthenia, pyrexia, and hematologic and gastrointestinal toxicities
  • • Overall rates of grade ≥3 adverse events were similar in both arms (66% with low dose alnodesertib plus gemcitabine vs 63% with gemcitabine alone), although grade ≥3 anemia and thrombocytopenia were more common with the combination
    • No treatment‑related deaths or cases of febrile neutropenia were reported in either arm of the study

“The encouraging clinical signals we observed in patients when low dose alnodesertib was added to gemcitabine suggest that this approach warrants further evaluation,” said Principal Investigator, Antonio Gonzalez-Martin, MD, PhD, Director of the Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra. “With approximately 70% of patients with ovarian cancer eventually relapsing following platinum-based chemotherapy, there is a high unmet need for promising new therapies like alnodesertib to improve clinical outcomes in platinum-resistant HGSOC and other tumors with high replication stress.”

About alnodesertib
Alnodesertib, formerly known as ART0380, is a potential first-in-class, orally administered, selective small molecule inhibitor of ataxia-telangiectasia and Rad3-related protein (ATR). It is designed to be used in combination with DNA‑damaging agents and is being evaluated across multiple tumor types characterized by high endogenous replication stress. Artios’ differentiated approach combines alnodesertib with low‑dose irinotecan to exploit replication stress in cancers such as ATM protein–deficient metastatic colorectal and pancreatic cancer, and other chemotherapies, like gemcitabine, to address platinum-resistant high-grade serous ovarian cancer (HGSOC).

About Artios Pharma Ltd.
Artios’ mission is to develop new classes of medicines that harness DNA Damage Response (DDR) pathways, targeting DNA replication stress and synthetic lethality, to deliver meaningful survival benefits for patients with cancer. Its three potentially first-in-class programs, each with a novel mechanism of action, include ATR inhibitor alnodesertib, the DNA polymerase theta (Polθ) inhibitor ART6043, and a preclinical portfolio of DDRi-ADC candidates with novel payloads. Together, these programs are designed to eliminate cancer cells’ survival mechanisms, driving cancer cell death and improving clinical outcomes.

Visit our website at www.artios.com to learn more about Artios.

For more information, please contact:
Trophic Communications
Jacob Verghese or Verena Schossmann
Tel: +49 151 7441 6179
Email: artios@trophic.eu

Ardena Appoints Paul Edwards as Chief People Officer




Ardena Appoints Paul Edwards as Chief People Officer

Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical contract development and manufacturing organizatin (CDMO) and bioanalytical contract research organization (CRO) advancing precision medicines, today announces the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, strengthening organizational capability and supporting the company’s continued international growth. 

Paul brings over 30 years of Human Resources leadership experience in complex, science-driven organizations. He joins Ardena after 16 years at Catalent Pharma Solutions, where he most recently served as Vice President, Human Resources. In that role, he led international HR teams across multiple business units and geographies, shaping people strategies aligned with operational expansion, organizational design and leadership development. 

At Ardena, Paul will focus on strengthening leadership capability, building a high-performance culture and ensuring the organization is structured to support productivity, speed and scalability. His mandate includes simplifying structures, clarifying accountability and developing the talent and engagement frameworks required to enable efficient execution across the business. 

Jeremie Trochu, Chief Executive Officer of Ardena, commented: “I’m delighted to welcome Paul onto our team. His track record in leading global HR organizations within the biopharma services sector makes him a very strong addition to our executive team. As Ardena continues to expand its capabilities and footprint internationally, investing in our people, leadership and culture is essential to delivering for our customers. Paul will play a key role in ensuring our organization evolves in line with our strategic ambitions.” 

Paul Edwards added: “Ardena has a clear strategy and very strong scientific and technical foundations. I look forward to working with my new colleagues across the organization to further develop our leadership capability, support talent development and foster a high-performance culture that enables sustainable growth.” 

Paul holds a joint honours degree in Law and Politics from Durham University in the United Kingdom and is based in New Jersey, USA. 

About Ardena 

Ardena is a specialist pharmaceutical CDMO and bioanalytical CRO dedicated to advancing precision medicines. Through integrated services spanning drug substance, drug product, nanomedicines, bioanalytical services and CMC regulatory support, Ardena supports innovative and complex molecules from development to commercialization. 

Attachment

• Paul Edwards, Chief People Officer, Ardena

Tectonic Therapeutic to Participate in March Investor Conferences




Tectonic Therapeutic to Participate in March Investor Conferences

WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026.

The live fireside chats can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their TD Cowen and Leerink representatives to schedule meetings.

About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.

CONTACT: Contacts:

Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

Media:
Kathryn Morris
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com

Tectonic Therapeutic to Participate in March Investor Conferences




Tectonic Therapeutic to Participate in March Investor Conferences

WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026.

The live fireside chats can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their TD Cowen and Leerink representatives to schedule meetings.

About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.

CONTACT: Contacts:

Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

Media:
Kathryn Morris
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com